Part D Gap Rebates Boost Medicare Rx Spending To 9% Gain In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug spending by the Medicare program increased more than by Medicaid or by private payers in 2010, according to an analysis by CMS; expenditures in Medicaid and by private insurance were level with the previous year and consumer out-of-pocket spending declined. Total drug spending across-the-board rose 1.2% to $259 billion.
You may also be interested in...
Reimbursement News, In Brief
Updates on Medicare’s ACO program, drug spending trends and Medicare coverage of IVIG.
Donut Hole Discounts Would Cost Medicare $17.4 Bil.; AARP Wants Phase Out
The pharmaceutical industry proposal to provide 50 percent discounts on the price of branded drugs for Medicare Part D beneficiaries in the donut hole would wind up costing the federal government $17.4 billion over 10 years, according to estimates by the Congressional Budget Office and the Joint Committee on Taxation released Sept. 16
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.